Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Noradrenaline and 5‐hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.

Noradrenaline and 5‐hydroxytryptamine modulation of brain dopamine function: implications for the... 1 Dopamine deficiency in the brain is the prime biochemical deficit in Parkinson's disease, but loss of noradrenaline and 5HT also may contribute. 2 In rats, 5HT‐containing neurones originating from the dorsal and median raphe nuclei innervate forebrain dopamine‐containing areas so as to impose an inhibitory regulatory tone on dopamine function. However, this interaction between brain dopamine and 5HT‐ containing neuronal systems is complex, and the effect produced appears dependent on the relative activity of each system. 3 Anatomical evidence for innervation of dopamine‐containing brain regions by noradrenaline fibres in the rat is scanty, but functional studies suggest the existence of inputs which facilitate dopamine function. 4 Drug therapy designed to increase or decrease brain 5HT function has had no consistent effect in Parkinson's disease. 5 Manipulation of brain noradrenergic activity in Parkinson's disease had little effect, although the noradrenaline precursor L‐threo‐DOPS may reduce freezing attacks. 6 Until more specific drug molecules are available the role of brain noradrenergic and 5HT mechanisms in Parkinson's disease remains uncertain. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Clinical Pharmacology Wiley

Noradrenaline and 5‐hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.

Loading next page...
 
/lp/wiley/noradrenaline-and-5-hydroxytryptamine-modulation-of-brain-dopamine-7mvWzS30mR

References (3)

Publisher
Wiley
Copyright
Copyright © 1983 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0306-5251
eISSN
1365-2125
DOI
10.1111/j.1365-2125.1983.tb05876.x
Publisher site
See Article on Publisher Site

Abstract

1 Dopamine deficiency in the brain is the prime biochemical deficit in Parkinson's disease, but loss of noradrenaline and 5HT also may contribute. 2 In rats, 5HT‐containing neurones originating from the dorsal and median raphe nuclei innervate forebrain dopamine‐containing areas so as to impose an inhibitory regulatory tone on dopamine function. However, this interaction between brain dopamine and 5HT‐ containing neuronal systems is complex, and the effect produced appears dependent on the relative activity of each system. 3 Anatomical evidence for innervation of dopamine‐containing brain regions by noradrenaline fibres in the rat is scanty, but functional studies suggest the existence of inputs which facilitate dopamine function. 4 Drug therapy designed to increase or decrease brain 5HT function has had no consistent effect in Parkinson's disease. 5 Manipulation of brain noradrenergic activity in Parkinson's disease had little effect, although the noradrenaline precursor L‐threo‐DOPS may reduce freezing attacks. 6 Until more specific drug molecules are available the role of brain noradrenergic and 5HT mechanisms in Parkinson's disease remains uncertain.

Journal

British Journal of Clinical PharmacologyWiley

Published: Apr 1, 1983

There are no references for this article.